with passion


Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

Bologna, 31 January 2024, 22:01 CET – Alfasigma S.p.A. is pleased to announce the successful completion of the transaction to acquire the Jyseleca® (filgotinib) business from Galapagos NV (Euronext & NASDAQ: GLPG) for up to €170 million. This marks a significant milestone for the company’s international growth strategy and follows both the signing of the agreement announced on 2 January 2024 and of the Letter of Intent announced on 30 October 2023.

Read more

Therapeutic areas


Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).


Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.


In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.

Nutraceuticals & Medical foods

With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.



During COVID-19 emergency, we strived to solidify and maintain our relationships with stakeholders by supporting them through numerous initiatives across the world.

You’re entering Alfasigma global website

I agree